Combined company will operate as EOM Pharmaceuticals Holdings, Inc. advancing a pipeline of novel immunomodulatory agents including EOM613 currently in clinical trials in Brazil as a potential treatment for severely ill COVID-19 patients
Combined company plans to continue at this time to trade on the OTC Markets
PR Newswire
MONTVALE, N.J. and LOS ANGELES, Dec. 2, 2021